1. Pink Sheet
  2. >>Product Reviews

Shutdown Week Three: Sponsors With Upcoming User Fee Dates Should Start Sweating

 
• By Derrick Gingery

US FDA has enough carryover funding for another month of operations, Commissioner Gottlieb says, potentially endangering late February and March review goals.

FDAEntrance_1200x675

As the partial shutdown of the US FDA enters its third week, sponsors with user fee goals in late February and beyond may be feeling a little more anxious and hoping for a resolution of the stand off between President Trump and Congressional Democrats over funding of a boarder wall.

The agency has been able to maintain many review functions during the shutdown with existing user fee dollars, but Commissioner...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Product Reviews

More from Pink Sheet

Advocates Want New Bipartisan PBM Reform Package To Stand Alone

 
• By Leslie Small

A new PBM reform package has familiar provisions, but stakeholders want it to move as a stand-alone bill, rather than as part of a larger legislative vehicle.

Gilead’s Lenacapavir Up For EMA Verdict Amid Packed CHMP Meeting Agenda

 
• By Vibha Sharma

The European Medicines Agency’s, human medicines committee, the CHMP, is this week poised to issue opinions on potential marketing approvals for 17 products.

Gene Therapy Elevidys Among Six Orphan Drugs Awaiting EU Marketing Verdict

 
• By Vibha Sharma

The European Medicines Agency is expected to decide whether to recommend EU-wide marketing authorization for six orphan-designated medicines that are all already approved in the US.